Background: Androgens are generally immunosuppressive, and men with untreated hypogonadism are at increased risk for autoimmune conditions. To date, there has been no evidence linking androgen deprivation therapy (ADT) to autoimmune diseases, including rheumatoid arthritis (RA). We investigated the association between ADT and RA in patients with prostate cancer.
Introduction
Androgen deprivation therapy (ADT) has been one of the mainstays of treatment for high-and certain intermediate-risk localized and locally advanced prostate cancer patients treated with radiation, as well as those with nodal and metastatic disease. Despite its survival benefit, ADT causes significant adverse effects, such as hot flashes; sexual dysfunction; metabolic derangements including sarcopenic obesity, dyslipidemia, and diabetes; fractures [1] ; and possibly cardiac [2, 3] , cognitive [4] , and psychiatric effects [5] .
Testosterone is thought to have a predominately suppressive role on multiple aspects of the immune system [6] , which may partly explain the higher incidence of autoimmune diseases, including rheumatoid arthritis (RA), in women [6] and hypogonadal men [7, 8] . However, to date, there has been no evidence linking ADT to the development of autoimmune diseases, including RA. Therefore, we investigated the association between receipt of pharmacologic ADT and new diagnoses of RA using a large population-based cohort of men with localized prostate cancer.
Patients and methods

Data source
Patients were identified from the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database. The SEER program collects demographic and clinicopathologic information from population-based cancer registries from 18 regions in the United States, capturing 28% of the population [9] . Medicare provides federal health insurance for approximately 97% of patients age 65 years or older.
Study cohort
We identified 126 213 men age 66 years or older diagnosed with stages I-III prostate cancer from 1992 through 2006 who had only 1 malignancy in SEER, information on the clinical T stage and tumor grade, and both Medicare Part A and B data without enrollment in a health maintenance organization from 1 year before prostate cancer diagnosis through death or end of follow-up in 2011 ( Figure 1 ). Patients who died 1 month after prostate cancer diagnosis (N ¼ 510), received orchiectomy (N ¼ 2160), or began ADT >6 months after prostate cancer diagnosis were excluded (N ¼ 15 394). Since follow-up for patients who received ADT began at the time of ADT initiation, the median time of ADT initiation (72 days after prostate cancer diagnosis) was used as the start of follow-up for patients who did not receive ADT. Men who did not receive ADT and died before start of follow-up (N ¼ 457), as well as those with a prior history of RA, determined by the presence of an RA diagnosis in Medicare in the year before prostate cancer diagnosis based on International Classification of Diseases, Ninth Revision (ICD-9) codes (supplementary Table S1 , available at Annals of Oncology online; N ¼ 2375), were excluded. Lastly, patients missing information on the Health Service Area (HSA, N ¼ 14) were removed. The final study cohort comprised of 105 303 patients.
Demographic and clinicopathologic characteristics
Demographic characteristics obtained from SEER included age at diagnosis, race, year of diagnosis, marital status, region of residence, urban/rural residence, and county-level education and income levels. Additionally, we determined the Klabunde modification of the Charlson comorbidity index using Medicare claims data from the year before prostate cancer diagnosis [10] .
Treatments consisted of definitive therapy [radiation therapy (RT) or radical prostatectomy (RP)], with or without ADT, initiated within 6 months of prostate cancer diagnosis. Receipt of treatment was identified through Common Procedural Terminology/Healthcare Common Procedure Coding System codes in Medicare claims files (supplementary Table S1 , available at Annals of Oncology online). Duration of ADT in months equivalent was calculated based on methodology previously described and limited to the 2 years after initiation of ADT [11] . Followup began either at the time of ADT initiation for patients who received ADT or median time of ADT initiation (72 days after prostate cancer diagnosis) for patients who did not receive ADT.
Diagnosis of RA
Diagnosis of RA was determined by the presence of ICD-9 codes specific to RA (supplementary Table S1 , available at Annals of Oncology online) in Medicare claims data, including physician, outpatient, and inpatient claims. The ICD-9 codes used are based on previously validated codes [12] , with 714.4 (chronic postrheumatic arthropathy) excluded. Overall, 3619 and 2893 patients who did not and did receive ADT, respectively, were diagnosed with RA.
Statistical analysis
Patient characteristics were compared using v 2 test for categorical variables and Wilcoxon rank-sum test for continuous variables with clustering by HSA, using complete cases. The rates of RA diagnoses were determined using the Kaplan-Meier method and compared with log-rank test. v 2 test was utilized to compare 5-year rates of RA diagnoses. Propensity scores were calculated based on the patient's age, race, year of diagnosis, marital status, region of residence, urban/rural residence, county-level education and income levels, Charlson comorbidity index, tumor grade/ Gleason score, clinical T stage, and definitive therapy (RT, RP, or none), using complete cases. Covariate balance after propensity weighting was assessed to ensure that groups were well-balanced (supplementary Table  S2 , available at Annals of Oncology online). Cox regression, using death as the competing risk, with inverse probability of treatment weighting and clustered by HSA, was used to examine the association between receipt of any ADT and diagnosis of RA and whether the association was affected by the duration of ADT (1-6 months, 7-12 months or 13 months). A P trend was calculated by modeling the dose category as a continuous variable (0, 1, 2, and 3 corresponding to 0, 1-6, 7-12, and 13 months) to assess whether increasing duration of ADT was associated with a higher risk of RA.
All statistical testing was two-sided with a level of significance set at P < 0.05. Analyses were carried out using SAS version 9.4 (SAS Institute, Cary, NC) or Stata MP 14.1 (StataCorp, College Station, TX). An institutional review board waiver was obtained before undertaking this study. 
Results
Baseline patient characteristics
Baseline patient characteristics are listed in Table 1 . About 43% (N ¼ 44 785) of the study cohort received ADT. Significant differences were detected in age, year of diagnosis, marital status, region of residence, urban/rural residence, income level, tumor grade/differentiation, clinical T stage, Charlson comorbidity index score, and definitive therapy modality (all P < 0.001).
Median follow-up was 7 years (interquartile range 4-9 years) for patients who received ADT and 7 years (interquartile range 5-10 years) for those who did not receive ADT.
Risk of RA with receipt of any ADT
Patients who received any ADT had a significantly higher unadjusted rate of a new RA diagnosis (P < 0.001). At 5 years, 5.4% of patients who received any ADT were diagnosed with RA, compared with 4.4% of those who did not (P < 0.001), with a number needed to harm of 100 (Figure 2) .
On Cox regression with inverse probability of treatment weighting, receipt of any ADT was associated with a 23% increased risk of a new RA diagnosis [hazard ratio (HR) 1.23, 95% confidence interval (CI) 1.09-1.40, P ¼ 0.001].
Risk of RA by duration of ADT received
At 5 years, 5.1%, 5.6%, and 5.8% of men who received 1-6, 7-12, and 13 months of ADT, respectively, were diagnosed with RA, compared with 4.4% of those who did not receive ADT (all P < 0.001). The corresponding numbers needed to harm were 143 for 1-6 months, 83 for 7-12 months, and 71 for 13 months of ADT.
Compared with no ADT, 1-6 months, 7-12 months, and 13 months of ADT was associated with 19% (HR 1.19, 95% CI 1.06-1.33, P ¼ 0.003), 29% (HR 1.29, 95% CI 1.05-1.57, P ¼ 0.014), and 33% (HR 1.33, 95% CI 1.13-1.56, P < 0.001) increased risks of a new RA diagnosis, respectively, on Cox regression with inverse probability of treatment weighting, with P trend < 0.001 (Table 2 and Figure 3 ). 
Discussion
We found that patients who received any ADT had a 23% increased risk of being diagnosed with RA using a large population-based cohort of elderly men with localized prostate cancer after adjusting for demographic and clinicopathologic factors. There was a significant trend between an increased duration of ADT and higher risk of being diagnosed with RA, with the risk being 19% for 1-6 months, 29% for 7-12 months, and 33% for 13 months of ADT compared with no ADT. Overall, our analyses strongly suggest an association between the use of ADT and being diagnosed with RA in elderly men with prostate cancer.
Our results are the first clinical evidence that ADT may increase the propensity toward autoimmunity and add to the many known adverse effects of ADT. Physicians should discuss RA as a possible side-effect before initiating ADT, particularly if a longcourse of treatment is anticipated. Judicious use of ADT is warranted, notably for intermediate-risk patients where the potential for benefit must be carefully weighed against the potential for harm.
Androgens have been demonstrated to have predominately suppressive effects on the immune system [6] . Notably, castrated mice experience thymic enlargement, whereas androgen replacement induces thymic regression [13] . Mice and men receiving androgen suppression experience thymic regeneration with an increase in circulating T cells, including naive T cells from the thymus [14] . Given the central role of T cells in the pathogenesis of RA [15] , androgen-mediated thymic regeneration may be contributing to a higher risk of RA diagnoses in prostate cancer patients on ADT. Interestingly, immune checkpoint inhibitors targeting CTLA-4 and PD-1, which both act on T cells, have also been linked to inflammatory arthritis [16] .
While a large meta-analysis of randomized trials did not show an association between ADT and cardiovascular death [17] , observational data have consistently found an association between ADT and cardiovascular events [3] . While ADT increases the likelihood of the metabolic risk factors of cardiovascular disease, including diabetes and dyslipidemia, these risk factors should take many months or years to materialize into an excess of cardiovascular events. However, retrospective data demonstrated that an increased risk for cardiovascular events Follow-up (years) Figure 2 . Kaplan-Meier plot of patients with diagnoses of rheumatoid arthritis. P < 0.001 by log-rank test. appears within the first 6 months after ADT initiation in certain patients [2] . RA is a well-known risk factor for cardiovascular events, likely through increased inflammation [18] . The additional risk of cardiovascular events appears to increase rapidly following the development of RA, as a retrospective matched cohort study found the relative risk of myocardial infarction in the year after RA diagnosis to be 1.4 (95% CI 0.9-2.1) [19] , even though the risk for cardiovascular events is not elevated before RA diagnosis [20] . Taken together, these data suggest that inflammation secondary to RA may be contributing to an early increase in cardiovascular events in certain prostate cancer patients on ADT.
The results of this study should be interpreted with their limitations in mind. First, because of Medicare eligibility criteria, the study cohort was limited to men age 66 years or older at time of diagnosis, and our results may not be reflective of the association between ADT and new RA diagnoses for patients younger than 66 years. Second, established risk factors for RA include low socioeconomic and education levels and smoking [21] . We adjusted for the former two using inverse probability of treatment weighting, incorporating county-level income and education data into the propensity score. We did not have data on smoking, but we excluded all patients with >1 documented malignancy in SEER.
Third, we determined ADT use by the receipt of a luteinizing hormone-releasing hormone agonist or antagonist. It is possible that some patients who were deemed to not have received ADT were given an androgen receptor (AR) antagonist as monotherapy. However, the SEER-Medicare database available to us does not provide information on whether a patient received an AR antagonist. Therefore, we could not determine the risk of RA diagnoses associated with AR antagonist monotherapy. Additionally, 2160 patients in our initial study cohort were treated with orchiectomy, and 107 men from this group subsequently received a diagnosis of RA. The small number of events unfortunately meant that our analysis was underpowered to observe whether the use of orchiectomy was significantly associated with an increased risk of RA diagnoses. Fourth, while the median follow-up of the two groups were both 7 years, it is possible that the two groups differed in their level of engagement with healthcare services, which could affect how often patients in each group were diagnosed with RA. Lastly, this study is retrospective and subject to the limitations of retrospective analyses that cannot be fully accounted for.
Conclusion
In summary, consistent with the immunosuppressive properties of androgens, we demonstrated for the first time that ADT was associated with an elevated risk of being diagnosed with RA in this large cohort of elderly men with prostate cancer. The risk was higher with a longer duration of ADT. Linking ADT to an increased risk of being diagnosed with an autoimmune condition adds to mounting evidence of the adverse effects of ADT that should prompt physicians to thoughtfully weigh its risks and benefits.
